0000000000711283

AUTHOR

Mark Lomax

showing 1 related works from this author

Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial …

2012

The inhaled corticosteroid fluticasone propionate (fluticasone) and the long-acting β₂ agonist formoterol fumarate (formoterol) have been combined in a single aerosol inhaler fluticasone/formoterol (flutiform(®)). This study compared the efficacy and safety of fluticasone/formoterol with the combination product budesonide/formoterol (Symbicort(®) Turbohaler(®)).A randomized, double-blind, double-dummy, multicenter, Phase 3 study comprising a 7- (± 3) day screening, 2-4-week run-in, and 12-week treatment periods. Patients aged ≥ 12 years with moderate to severe persistent asthma for ≥ 6 months before screening and forced expiratory volume in one second (FEV₁) 50-80% predicted and ≥ 15% rever…

Pulmonary and Respiratory MedicineBudesonideAdultMaleAdolescentFluticasone propionateYoung AdultDouble-Blind Methodimmune system diseasesForced Expiratory VolumeFormoterol FumarateAdministration InhalationImmunology and AllergyMedicineHumansBudesonideFluticasoneAgedbusiness.industryInhalerDry Powder Inhalersrespiratory systemMiddle AgedAsthmarespiratory tract diseasesBronchodilator AgentsAndrostadienesDrug CombinationsBudesonide/formoterolEthanolaminesAnesthesiaPediatrics Perinatology and Child HealthSalbutamolFluticasoneFormoterol FumarateFemaleFormoterolbusinesshormones hormone substitutes and hormone antagonistscirculatory and respiratory physiologymedicine.drugThe Journal of asthma : official journal of the Association for the Care of Asthma
researchProduct